Supplementary Tables

|                     | Ever Use  | Current Use | Past Use |
|---------------------|-----------|-------------|----------|
| Control (Reference Group) |           |             |          |
| Oral                | 1.2 [-6, 9] |             | 0.2 [-8, 8] |
| Transdermal         | -5.2 [-11, 0.6] | -1.8 [-9, 6] | -1.80 [-9, 6] |
| Vaginal             | 1.7 [-4, 8] | 2.4 [-6, 11] | 2.4 [-6, 11] |
| Oral (Reference Group) |           |             |          |
| Transdermal         | -5.3 [-0.8, 0.1] |             | 3 [-15, 21] |
| Vaginal             | -2 [-18, 14] |             | -2.3 [-21, 26] |

Only 2 participants were currently using oral HT, therefore not enough participants to run analyses Adjusted for hypertension, age of menopausal onset, and vasomotor symptoms.

\(^a\) p<0.05 compared to reference group